Program
Please note that this meeting will take place as an in-person event in Toronto and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
Sunday, October 1, 2023
Welcome and Opening Keynote Lecture
Monday, October 2
Plenary Session 1: T-cell Biology
Plenary Session 2: Macrophages and Myeloid Cells
Plenary Session 3: Inhibitory Cells
Tuesday, october 3
Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Plenary Session 5: Metabolic Modulation of Anti-tumor Immunity
Plenary Session 6: TCR-targeted Immunotherapies
Wednesday, octoBer 4
Plenary Session 7: Spatial Profiling
Plenary Session 8: Synthetic Biology and Immune Cell Engineering
Plenary Session 9: Engineered Cytokines
Sunday, October 1, 2023
Registration
3-8 p.m.
Welcome and oPENInG Keynote Lecture
6:30-7:30 P.M.
Welcome and Introduction of Keynote Speaker
Philip D. Greenburg, Fred Hutchinson Cancer Research Center, Seattle, Washington
Keynote Lecture
Chasing T Cell Exhaustion
Crystal L. Mackall, Stanford University School of Medicine, Stanford, California
Opening reception
7:30-9:30 p.m.
Monday, october 2
Continental breakfast
7-8 a.m.
Plenary Session 1: T-cell Biology
Session Chair: Andrea Schietinger, Memorial Sloan Kettering Cancer center, New York, New York
8-10:05 A.M.
Critical role for Batf3-lineage dendritic cells within the tumor microenvironment
Thomas F. Gajewski, University of Chicago, Chicago, Illinois
Title to be announced
Andrea Schietinger
Elucidating mechanisms of immunotherapy response and resistance in pancreatic cancer
Ingunn Stromnes, University of Minnesota Medical School, Minneapolis, Minnesota
Regulation of exhausted CD8+ T cell differentiation by IKZF transcription factors*
Sinead M. Reading, Peter MacCallum Cancer Centre, Melbourne, Australia
Panel Discussion
bREAK
10:05-10:25 A.M.
pLENARY sESSION 2: MACROPHAGES AND MYELOID CELLS
Session Chair: Jennifer L. Guerriero, Brigham and Women’s Hospital, Boston, MASSACHUSETTS
10:25 A.M.-12:30 p.m.
Title to be announced
Matthew Krummel, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Title to be announced
Aaron M. Newman, Stanford University, Stanford, California
Unraveling the complexities of tumor associated macrophages for anti-cancer therapy of breast cancer
Jennifer L. Guerriero
Lyn kinase regulates myeloid-cell responses to mammary tumors*
Joseph T. Greene, Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota
Panel Discussion
Lunch on Own/Free Time
12:30-2:30 P.M.
pLENARY sESSION 3: Inhibitory Cells
Session Chair: PAMELA S. OHASHI, UHN PRINCESS MARGARET CANCER CENTRE, TORONTO, ONTARIO, CANADA
2:30-4:35 P.M.
Title to be announced
Robert D. Schreiber, Washington University School of Medicine in St. Louis, Missouri
Title to be announced
Pamela S. Ohashi
PMN-MDSC in regulation of immune suppressive microenvironment in cancer
Dmitry Gabrilovich, AstraZeneca, Philadelphia, Pennsylvania
Hypoxia promotes inflammatory fibroblast formation in pancreatic cancer*
Ashley M. Mello, University of Michigan, Ann Arbor, Michigan
Panel Discussion
pOSTER SESSION A/RECEPTION
4:45-7:00 P.M.
Abstracts to be presented at the conference
eVENING OFF/DINNER ON OWN
7:00 P.M.
tUESDAY, OCTOBER 3
Continental Breakfast
7-8 A.M.
Plenary Session 4: Lymphocyte Subsets Impacting Anti-tumor Immunity
Session Chair: Dario a. a. vignali, University of pittsburgh, Pittsburgh, pennsylvania
8-10:05 A.M.
Interferon modification of T cell function and response to immunotherapy
David G. Brooks, University of Toronto, Toronto, Ontario, Canada
Title to be announced
Tak W. Mak, UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada
LAG-3: The third checkpoint inhibitor & its synergistic interactions with PD1
Dario A. A. Vignali
Temporal single cell profiling identifies B-cell specific checkpoint molecules that regulate anti-tumor immunity*
Lloyd Bod, Massachusetts General Hospital, Boston, Massachusetts
Panel Discussion
Break
10:05-10:25 A.M.
Plenary Session 5: Metabolic Modulation of Anti-Tumor Immunity
Session Chair: Greg M. delgoffe, UPMC Hillman cancer center, pittsburgh, pennsylvania
10:25 a.m.-12:30 p.m.
Title to be announced
Greg M. Delgoffe
Obesity and immunometabolism in cancer immunotherapy
Jeffrey C. Rathmell, Vanderbilt University Medical Center, Nashville, Tennessee
Title to be announced
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland
Dgat1 camouflages sexual dimorphism in anti-tumor CD8+ T cell immunity*
Alaa Madi, German Cancer Research Center, Heidelberg, Germany
Panel Discussion
lunch on own/free time
12:30-2:30 p.m.
plenary session 6: tcr-targeted immunotherapies
Session Chair: Catherine j. Wu, dana-farber cancer institute, boston, massachusetts
2:30-4:35 p.m.
Title to be announced
Catherine J. Wu
Cancer Neoantigens: From Discovery to the Clinic
Nina Bhardwaj, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
Title to be announced
Paul G. Thomas, St. Jude Children’s Research Hospital, Memphis, Tennessee
Hallmarks of CD8 T cell dysfunction are established within hours of tumor antigen encounter prior to cell division*
Mary Philip, Vanderbilt University Medical Center, Nashville, Tennessee
Panel Discussion
Poster session b/reception
4:45-7:00 p.m.
Posters to be presented at the conference
Evening Off/Dinner on own
7:00 P.M.
Wednesday, october 4
Continental Breakfast
7-8 a.m.
plenary session 7: spatial profiling
sESSION cHAIR: R. Michael Angelo, Stanford University, Palo Alto, California
8-9:50 a.m.
Identifying regulators of tumor immunity by spatial functional genomics
Brian D. Brown, Icahn School of Medicine at Mount Sinai, New York, New York
A spatial framework for predicting outcome in breast cancer
R. Michael Angelo
Recirculating tumor-specific T cell responses as biomarkers for virally driven cancers
Evan Newell, Fred Hutchinson Cancer Research Center, Seattle, Washington
Panel Discussion
Break
9:50-10:05 a.m.
Plenary session 8: synthetic biology and immune cell engineering
Session Chair: Phillip D. Greenberg, Fred Hutchinson Cancer Research Center, SEattle, Washington
10:05-11:55 a.m.
Title to be announced
Carl H. June, Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania
Title to be announced
Philip D. Greenberg
Title to be announced
Michael Sadelain, Memorial Sloan Kettering Cancer Center, New York, New York
Panel Discussion
Break
11:55 a.m.-12:10 p.m.
plenary session 9: engineered cytokines
Session Chair: Mario Sznol, Yale University, New Haven, Connecticut
12:10-2 p.m.
Title to be announced
Pablo Umana, Roche, Schlieren, Switzerland
Title to be announced
Ivana Djuretic, Asher Biotherapeutics, Inc., South San Francisco, California
Title to be announced
Mario Sznol
closing comments and departure
2 p.m.
Mario Sznol, Yale University, New Haven, Connecticut
* Short talk from proffered paper